(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued
(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued
Total investment in the field now over $65 million New York, NY February 11, 2015 — To conclude Ovarian Cancer Research Fund’s 20th anniversary year, $6.453 million has been awarded in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. This brings OCRF’s total investment in research and related educational … Continued
(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational and support initiatives to nearly $70 million. The twenty new OCRF research grants have been awarded to top scientists at fourteen leading medical centers across … Continued
(February 4, 2014) In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy. The work was led by Dr. Kenneth Nephew, who was funded through an OCRF Program Project Development Grant. The development of resistance to chemotherapy in ovarian cancer … Continued
(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer. The findings were published this month in Nature Communications. Previous studies have identified 12 epithelial ovarian cancer susceptibility alleles (an allele is one of two or … Continued
(Feb. 2, 2015) Recent studies have suggested that ovarian cancer predominantly arises within the fallopian tubes or the uterus. A group of Swedish researchers hypothesized that surgical removal of the fallopian tubes (salpingectomy) is associated with a reduced risk for ovarian cancer. In the study, which involved hundreds of thousands of women, researchers compared women who … Continued
(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr. Chandler spearheaded a team of researchers at University of North Carolina that developed a mouse model of clear cell ovarian cancer that accurately portrays the … Continued
(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was … Continued
(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to ten years after diagnosis. The researchers found that BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and, in BRCA1 … Continued
The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded scope that incorporates detailed clinical information about the patient’s … Continued
A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer. Its main purpose is to keep the best quality of life … Continued
Get email updates about research news, action alerts, and ways to join the fight.
